Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial

医学 安慰剂 益生菌 内科学 泌尿系统 安慰剂对照研究 抗生素 不利影响 胃肠病学 随机对照试验 临床试验 双盲 微生物学 细菌 病理 生物 替代医学 遗传学
作者
Varsha Gupta,Paola Mastromarino,Ritu Garg
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:78 (5): 1154-1161 被引量:9
标识
DOI:10.1093/cid/ciad766
摘要

Abstract Background Widespread antibiotic resistance has sparked interest in the identification of nonantibiotic strategies, particularly probiotics for the prevention of recurrent urinary tract infections (UTIs). We evaluated the effectiveness of prophylactic probiotic supplementation through oral and intravaginal routes in the prevention of recurrent UTIs. Methods This double-blind, placebo-controlled study enrolled 174 premenopausal women with a history of recurrent UTIs and randomized them to 1 of the 4 treatment groups: placebo (G1, oral placebo + vaginal placebo), oral probiotic (G2, oral lactic acid bacteria and bifidobacteria + vaginal placebo), vaginal probiotic (G3, oral placebo + vaginal lactobacilli), and probiotic combination (oral lactic acid bacteria and bifidobacteria + vaginal lactobacilli), for 4 months. Participants were followed up for symptomatic UTIs for 1 year. The primary end points were the number of symptomatic UTIs at 4 months, the proportion of participants with at least 1 symptomatic UTI, and the time to the first symptomatic UTI. Results The incidence of UTI at 4 months in G1, G2, G3, and G4 was 70.4%, 61.3%, 40.9%, and 31.8%, respectively. The mean number of symptomatic UTI recurrences at 4 months was significantly lower (P < .05) in G3 (1.06) and G4 (1.07) compared with G1 (2.1) and G2 (1.63). Further, the time to first symptomatic UTI (days) was significantly longer (P < .05) in G3 (123.8) and G4 (141.8) compared with G1 (69.3) and G2 (71.9). Probiotic supplementations were well tolerated with no serious adverse events. Conclusions Prophylactic supplementation with either vaginal probiotics or in combination with oral probiotics demonstrated effectiveness in preventing recurrent symptomatic UTI episodes. Clinical Trials Registration Registered at Clinical Trials Registry India (CTRI): CTRI/2014/02/004425 (https://ctri.nic.in).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
orixero应助小庄采纳,获得10
刚刚
1秒前
侦察兵发布了新的文献求助10
1秒前
司徒元瑶完成签到 ,获得积分10
1秒前
梓榆发布了新的文献求助10
1秒前
1秒前
sweetbearm应助通~采纳,获得10
1秒前
斯文败类应助成就映秋采纳,获得10
2秒前
123456完成签到,获得积分10
2秒前
2秒前
moonlin完成签到 ,获得积分10
2秒前
3秒前
4秒前
深情安青应助科研通管家采纳,获得10
4秒前
5秒前
wanci应助科研通管家采纳,获得10
5秒前
英俊的铭应助科研通管家采纳,获得10
5秒前
思源应助蟹黄堡不打折采纳,获得10
5秒前
Lily应助科研通管家采纳,获得40
5秒前
敬老院N号应助科研通管家采纳,获得30
5秒前
zzzq应助科研通管家采纳,获得10
5秒前
酷波er应助科研通管家采纳,获得10
5秒前
天天快乐应助科研通管家采纳,获得10
5秒前
大个应助科研通管家采纳,获得10
5秒前
慕青应助科研通管家采纳,获得10
5秒前
皮皮完成签到 ,获得积分10
5秒前
sallltyyy发布了新的文献求助10
5秒前
5秒前
研友_VZG7GZ应助科研通管家采纳,获得10
5秒前
Lucas应助科研通管家采纳,获得10
5秒前
QPP完成签到,获得积分10
5秒前
科研通AI5应助科研通管家采纳,获得10
5秒前
FashionBoy应助科研通管家采纳,获得10
5秒前
科研通AI5应助科研通管家采纳,获得30
5秒前
喜悦中道应助科研通管家采纳,获得10
5秒前
wzxxxx发布了新的文献求助10
6秒前
冬瓜炖排骨完成签到,获得积分10
6秒前
6666发布了新的文献求助10
6秒前
BB发布了新的文献求助10
7秒前
冷静雅青完成签到 ,获得积分10
8秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527884
求助须知:如何正确求助?哪些是违规求助? 3108006
关于积分的说明 9287444
捐赠科研通 2805757
什么是DOI,文献DOI怎么找? 1540033
邀请新用户注册赠送积分活动 716904
科研通“疑难数据库(出版商)”最低求助积分说明 709794